All
Combination Continues to Show Impressive Outcomes in Melanoma
November 3rd 2017In an interview with CURE, Postow, a medical oncologist specializing in melanoma at Memorial Sloan Kettering Cancer Center, discussed the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.
Drug Granted Breakthrough Status to Treat Relapsed or Refractory Myeloma
November 3rd 2017A new drug, GSK2857916, was granted a breakthrough therapy designation by the FDA to treat patients who have relapsed or refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the agent.
Don't Claim Marijuana Products Cure Cancer, FDA Warns
November 2nd 2017Four companies drew the ire of the Food and Drug Administration this week for claiming that their marijuana-derived products can treat or cure cancer. The agency issued letters of warning, and threatened punitive action if the companies do not correct the violations.
Early Palliative Care Improves Coping Strategies and Quality of Life
November 1st 2017A study presented at the 2017 Palliative and Supportive Care in Oncology Symposium examined the effects of early-integrated palliative care on patients with advanced/incurable lung or non-colorectal gastrointestinal cancers.
FDA Approves Calquence for Mantle Cell Lymphoma
October 31st 2017Calquence (acalabrutinib) was granted an accelerated approval by the FDA to treat adult patients with mantle cell lymphoma (MCL) following at least one prior therapy. The approval was based on objective response rates (ORR) in a single-arm trial.